These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 9746770)

  • 1. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
    Grimwade D; Walker H; Oliver F; Wheatley K; Harrison C; Harrison G; Rees J; Hann I; Stevens R; Burnett A; Goldstone A
    Blood; 1998 Oct; 92(7):2322-33. PubMed ID: 9746770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
    Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
    Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
    Grimwade D; Walker H; Harrison G; Oliver F; Chatters S; Harrison CJ; Wheatley K; Burnett AK; Goldstone AH;
    Blood; 2001 Sep; 98(5):1312-20. PubMed ID: 11520776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
    Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
    Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
    Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
    Grimwade D; Hills RK; Moorman AV; Walker H; Chatters S; Goldstone AH; Wheatley K; Harrison CJ; Burnett AK;
    Blood; 2010 Jul; 116(3):354-65. PubMed ID: 20385793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
    Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
    Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
    Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR
    Blood; 2000 Dec; 96(13):4075-83. PubMed ID: 11110676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).
    Kainz B; Heintel D; Marculescu R; Schwarzinger I; Sperr W; Le T; Weltermann A; Fonatsch C; Haas OA; Mannhalter C; Lechner K; Jaeger U
    Hematol J; 2002; 3(6):283-9. PubMed ID: 12522450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint.
    Archimbaud E; Charrin C; Magaud JP; Campos L; Thomas X; Fière D; Rimokh R
    Leukemia; 1998 Jan; 12(1):25-33. PubMed ID: 9436917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Medical Research Council Leukaemia Working Parties.
    Grimwade D; Walker H; Oliver F; Wheatley K; Clack R; Burnett A; Goldstone A
    Bone Marrow Transplant; 1997 Jun; 19(11):1117-23. PubMed ID: 9193755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.
    Dastugue N; Payen C; Lafage-Pochitaloff M; Bernard P; Leroux D; Huguet-Rigal F; Stoppa AM; Marit G; Molina L; Michallet M
    Leukemia; 1995 Sep; 9(9):1491-8. PubMed ID: 7658718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
    Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
    Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse.
    Weltermann A; Fonatsch C; Haas OA; Greinix HT; Kahls P; Mitterbauer G; Jäger U; Kainz B; Geissler K; Valent P; Sperr WR; Knöbl P; Schwarzinger I; Gleiss A; Lechner K
    Leukemia; 2004 Feb; 18(2):293-302. PubMed ID: 14671635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
    Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
    Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.